Dr.Kang Tiebang

Principal Investigatorof State Key Laboratory of Oncology in South China     

Email: kangtb@mail.sysu.edu.cn,kangtb@sysucc.org.cn

Research area

• Regulationof Cell Cycle

• Basicresearch of tumor-targeted therapy

• Regulationof tumor metastasis.

Research Results

• GSK-3 gene was found to play a role of oncogenein osteosarcoma cancer occurrence and development through NFkB pathways.GSK-3/NF-kB pathway can be used as therapeutic targets and prognosticindicators in patients with osteosarcoma. This study provided new thoughts andtargets for the integrated treatment of osteosarcoma (J. Natl Cancer Inst, 2012)

• Chk1 was found to work as oncogene in livercancer, and its important substrate is SYK (L) that is a tumor suppressor gene.SYK (L) is degraded through its phosphorylation by Chk1. It showed that SYK (L)and Chk1 protein levels were correlated negatively. Chk1 can be used asprognostic indicators of liver cancer patients and therapeutic targets, and Chk1suppressor may enhance the sensitivity of liver cancer cells to chemotherapy. (J.Clin. Invest., 2012)

• It was the first study to ever report hSSB1 wasa chaperone that can regulate stability of p53 protein and adjust p300-mediatedacetylation of p53 in order to control transcriptional activity of p53. (CellRes., 2012). Meanwhile, as a chaperone, hSSB1 also can directly regulatestability of p21 protein (Oncogene, 2011).